Page last updated: 2024-08-24

bromfenac and Retinal Diseases

bromfenac has been researched along with Retinal Diseases in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bom Aggio, F; Bottós, JM; Farah, ME; Rodrigues, EB	1
Bernini, M; Costagliola, C; De Ferrari, F; Morescalchi, F; Russo, A; Semeraro, F; Turano, R; Vezzoli, S	1
Awh, CC; Busbee, BG; Cleary, TS; Daniel, P; Heier, JS; Stoller, GL; Waterbury, LD	1

Reviews

1 review(s) available for bromfenac and Retinal Diseases

Article	Year
Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Retinal Diseases. Developments in ophthalmology, 2016, Volume: 55 Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Benzophenones; Bromobenzenes; Diclofenac; Humans; Ketorolac; Phenylacetates; Retinal Diseases	2016

Trials

2 trial(s) available for bromfenac and Retinal Diseases

Article	Year
REDUCTION OF VITREOUS PROSTAGLANDIN E2 LEVELS AFTER TOPICAL ADMINISTRATION OF INDOMETHACIN 0.5%, BROMFENAC 0.09%, AND NEPAFENAC 0.1. Retina (Philadelphia, Pa.), 2016, Volume: 36, Issue:6 Topics: Administration, Topical; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Benzophenones; Biological Availability; Bromobenzenes; Chromatography, High Pressure Liquid; Dinoprostone; Double-Blind Method; Female; Humans; Indomethacin; Male; Ophthalmic Solutions; Phenylacetates; Prospective Studies; Retinal Diseases; Tissue Distribution; Vitrectomy; Vitreous Body	2016
Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Retina (Philadelphia, Pa.), 2009, Volume: 29, Issue:9 Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Benzophenones; Biological Availability; Bromobenzenes; Chromatography, High Pressure Liquid; Dinoprostone; Female; Humans; Ketorolac; Male; Mass Spectrometry; Middle Aged; Ophthalmic Solutions; Phenylacetates; Retinal Diseases; Tissue Distribution; Vitrectomy; Vitreous Body	2009

Article

Year

REDUCTION OF VITREOUS PROSTAGLANDIN E2 LEVELS AFTER TOPICAL ADMINISTRATION OF INDOMETHACIN 0.5%, BROMFENAC 0.09%, AND NEPAFENAC 0.1.

Retina (Philadelphia, Pa.), 2016, Volume: 36, Issue:6

Topics: Administration, Topical; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Benzophenones; Biological Availability; Bromobenzenes; Chromatography, High Pressure Liquid; Dinoprostone; Double-Blind Method; Female; Humans; Indomethacin; Male; Ophthalmic Solutions; Phenylacetates; Prospective Studies; Retinal Diseases; Tissue Distribution; Vitrectomy; Vitreous Body

2016

Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%.

Retina (Philadelphia, Pa.), 2009, Volume: 29, Issue:9

Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Benzophenones; Biological Availability; Bromobenzenes; Chromatography, High Pressure Liquid; Dinoprostone; Female; Humans; Ketorolac; Male; Mass Spectrometry; Middle Aged; Ophthalmic Solutions; Phenylacetates; Retinal Diseases; Tissue Distribution; Vitrectomy; Vitreous Body

2009